Atezolizumab (MPDL3280)—a humanized monoclonal IgG1k antibody—exhibits high affinities to human and murine PD-L1 (KD = 0.43 and 0.13 nM, respectively) and succeeded in clinical trials treating several kinds of cancers including non-small cell lung carcinoma, renal cell carcinoma, and triple negative breast cancer [81,82]. The gene discussed is CD274; the disease is triple-negative breast carcinoma.